THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) for THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 4th Quarter - Report (this page) | Jan 20, 2026 | $1,640,000 | Replaced |
| 4th Quarter - Amendment | Apr 20, 2026 | $1,670,000 | Yes |
What was lobbied
5 issue areas, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
Issues related to prior authorization.
| Lobbyist | Covered position, as disclosed |
|---|---|
| COURTNEY LAWRENCE | — |
| KARA SMITH | — |
Labor Issues/Antitrust/Workplace LBR
Issues related to competition in the health care marketplace.
| Lobbyist | Covered position, as disclosed |
|---|---|
| KATHRYN GALLAGHER | — |
| CHRISTOPHER HARTMANN | — |
| COURTNEY LAWRENCE | — |
| JULIEN MITCHELL RELFE | — |
| KARA SMITH | — |
| KRISTINA KAYE WEGER New | Health Policy and Communications Director, U.S. Rep. Blaine Luetkemeyer (MO); Intern, U.S. Sen. Roy Blunt (MO) |
Health Issues HCR
S. 864/H.R. 247, the Health Care Affordability Act of 2025 and issues relating to extension of Enhanced Advanced Premium Tax Credits (EAPTCs) including in the American Rescue Plan Act (ARPA) and the Inflation Reduction Act (IRA); Issues relating to implementation of the No Surprises Act.
| Lobbyist | Covered position, as disclosed |
|---|---|
| KATHRYN GALLAGHER | — |
| CHRISTOPHER HARTMANN | — |
| COURTNEY LAWRENCE | — |
| JULIEN MITCHELL RELFE | — |
| KARA SMITH | — |
| KRISTINA KAYE WEGER | — |
Defense DEF
H.R. 3838/S. 2296 Pharmacy issues related to the National Defense Authorization Act, FY2026.
| Lobbyist | Covered position, as disclosed |
|---|---|
| KATHRYN GALLAGHER | — |
| CHRISTOPHER HARTMANN | — |
| COURTNEY LAWRENCE | — |
| JULIEN MITCHELL RELFE | — |
| KARA SMITH | — |
Pharmacy PHA
"S. 1542/H.R.2214, the DRUG Act; H.R. 5378 Lower Costs, More Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.526, Pharmacy Benefit Manager Transparency Act." Issues related to the specialty drug market. Issues related to transparency.
| Lobbyist | Covered position, as disclosed |
|---|---|
| KATHRYN GALLAGHER | — |
| CHRISTOPHER HARTMANN | — |
| COURTNEY LAWRENCE | — |
| JULIEN MITCHELL RELFE | — |
| KARA SMITH | — |
| KRISTINA KAYE WEGER | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.